Somatostatin Analogue Catabolite Screening and Identification Using Vion IMS QTof with WebMetabase

Importance of the Topic

Understanding how modified peptides break down in biological systems is critical for designing more stable, effective peptide drugs. By characterizing catabolic pathways and rates, researchers can optimize peptide analogues to resist rapid clearance, improving their therapeutic potential.

Objectives and Overview of the Study

This study evaluated eight 14‐amino‐acid analogues of the hormone somatostatin to identify their serum catabolites and compare stability profiles. Samples were incubated in human serum over 11 time points up to 48 hours. High‐resolution, ion mobility–enabled LC‐MS data were acquired to detect peptide metabolites, and powerful software tools were employed to automate identification, scoring, and visualization of catabolic products.

Methodology

The analogues, featuring various D‐amino acid substitutions and noncanonical residues, were incubated at 37 °C in human serum. At 0 to 48 hours, aliquots were quenched and analyzed by UPLC coupled to ion mobility‐enabled QTof. Data acquisition used HDMSE (DIA) mode to collect both low‐energy precursor and high‐energy fragmentation information in a single run.

Used Instrumentation

• Vion IMS QTof Mass Spectrometer (Waters)
• ACQUITY UPLC I‐Class System and CSH C18 Columns
• UNIFI Scientific Information System with WebAPI
• Mass‐MetaSite 3.4.2 and WebMetabase 4.0 (Molecular Discovery Ltd.)

Main Results and Discussion

Catabolism predominantly occurred at the peptide tail, yielding N−1 (−71 Da) and N−2 (−128 Da) cleavage products. Ion mobility and collision cross‐section (CCS) measurements enhanced selectivity by filtering interferences and confirming metabolite identity. D‐amino acid substitutions at Ala[1], Cys[3], and Cys[14] demonstrated synergistic effects on stability. The most stable variant (peptide 95) showed markedly delayed and reduced metabolite formation compared to native somatostatin.

Benefits and Practical Applications

• Automated detection and scoring of catabolites expedites metabolite profiling workflows.
• Ion mobility–enabled CCS values improve confidence in compound identification.
• Cloud‐based WebMetabase allows global collaboration and shared data repositories.

Future Trends and Potential Uses

Integration of HELM notation bridges sequence representation with chemical structure details, fostering clearer communication in peptide design. Advances in ion mobility, AI‐driven data mining, and cloud computing will support higher throughput screening, more complex macromolecule analysis, and seamless data sharing across multidisciplinary teams.

Conclusion

This application of ion mobility–enhanced HRMS combined with automated software tools enabled in‐depth mapping of somatostatin analogue catabolism. Strategic D‐amino acid substitutions significantly improved serum stability. The approach demonstrates a robust platform for rapid, confident metabolite identification and supports rational peptide drug design.

References

1. Kirk J. et al. Waters Technology Brief 720006362EN, July 2018.
2. Kirk J. et al. Poster, IMSC 2018, Italy, PSTR134993803.